Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Efficacy of recombinant erythropoietin for the late treatment of anemia of prematurity in a level IV neonatal intensive care unit: a retrospective single-center cohort study

Abstract

Objective

To describe the population to which we administered recombinant erythropoietin and to determine the effectiveness of this treatment as quantified by the change in hematocrit.

Study design

This retrospective chart review study included infants who received erythropoietin for the treatment of anemia of prematurity.

Results

There were 132 infants representing 162 unique treatment courses included in the study. The average duration of therapy was 9 days (±7) and 6 doses (±2). The average change in hematocrit (Hct) was 6.2% (SD 3.9%, p < 0.001). Rise in Hct was associated with a higher number of rEPO doses (p < 0.001) and higher postmenstrual age (p < 0.001). In our small cohort we did not find an association between the number of rEPO doses and retinopathy of prematurity (ROP) requiring treatment.

Conclusion

Erythropoietin is safe and effective at treating anemia of prematurity as evidenced by a clinically and statistically significant increase in Hct from baseline.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Flowchart of courses reviewed, analyzed, and excluded.
Fig. 2: Individual response to rEPO was highly variable.
Fig. 3: Rise in hematocrit increases as the number of rEPO doses increases (p < 0.005).
Fig. 4: Rise in hematocrit increase with the number of days of rEPO therapy (p < 0.005).
Fig. 5: Higher PMA at the start of treatment was associated with a higher rise in hematocrit (p < 0.005).

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Villeneuve A, Arsenault V, Lacroix J, Tucci M. Neonatal red blood cell transfusion. Vox Sang. 2021;116:366–78.

    Article  PubMed  Google Scholar 

  2. Bell EF. Red cell transfusion thresholds for preterm infants: finally some answers. Arch Dis Child Fetal Neonatal Ed. 2022;107:126–30.

    Article  PubMed  Google Scholar 

  3. Colobatti R, Sainati L, Trevisanuto D. Anemia and transfusion in the neonate. Semin Fetal Neonatal Med. 2016;21:2–9.

    Article  Google Scholar 

  4. Christensen RD, Baer VL, Lambert DK, Ilstrup SJ, Eggert LD, Henry E. Association, among very-low birthweight neonates, between red blood cell transfusions in the week after birth and severe intraventricular hemorrhage. Transfusion. 2014;54:104–8.

    Article  PubMed  Google Scholar 

  5. Ohlsson A, Aher SM. Early erythropoiesis-stimulating agents in preterm or low birth weight infants. Cochrane Database Syst Rev. 2017;11:CD004863.

    PubMed  Google Scholar 

  6. Ohlsson A, Aher SM. Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants. Cochrane Database Syst Rev. 2020;1:CD004868.

    PubMed  Google Scholar 

  7. Maier RF, Obladen M, Müller-Hansen I, Kattner E, Merz U, Arlettaz R, et al. Early treatment with erythropoietin β ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000g. J Pediatr. 2002;141:8–15.

    Article  CAS  PubMed  Google Scholar 

  8. El-Lahony DM, Saleh NY, Habib MS, Shehata MA, El-Hawy MA. The role of recombinant human erythropoietin in neonatal anemia. Hematol Oncol Stem Cell Ther. 2020;13:147–51.

    Article  PubMed  Google Scholar 

  9. Ohls RK, Osborne KA, Christensen RD. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial. J Pediatr. 1995;126:421–6.

    Article  CAS  PubMed  Google Scholar 

  10. Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double blind, placebo-controlled study. J Pediatr. 1997;131:661–5.

    Article  CAS  PubMed  Google Scholar 

  11. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics. 2001;108:934–42.

    Article  CAS  PubMed  Google Scholar 

  12. Juul SE, Vu PT, Comstock BA, Wadhawan R, Mayock DE, Courtney SE, et al. Effect of high-dose erythropoietin on blood transfusions in extremely low gestational age neonates: post hoc analysis of a randomized clinical trial. JAMA Pediatr. 2020;174:933–43.

    Article  PubMed  Google Scholar 

  13. Salsbury DC. Anemia of prematurity. Neonatal Netw. 2001;20:13–20.

    Article  CAS  PubMed  Google Scholar 

  14. Strauss RG. Anemia of prematurity: pathophysiology & treatment. Blood Rev. 2010;24:221–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Romagnoli C, Zecca E, Gallini F, Zuppa PGAA. Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity? Eur J Pediatr. 2000;159:627–34.

    Article  CAS  PubMed  Google Scholar 

  16. Fischer HS, Reibel NJ, Bührer C, Dame C. Effect of early erythropoietin on retinopathy of prematurity: a stratified meta-analysis. Neonatology. 2023;120:566–76.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

M. David Gothard, BS, MS of BioStats of Ohio, Inc. for his support in statistical analysis and power calculations.

Author information

Authors and Affiliations

Authors

Contributions

JC was responsible for literature review, project design, data collection, manuscript composition. JDM and JLM were responsible for project design, literature review, manuscript review. RMR was responsible for project design, literature review, data analysis, manuscript review. MLN was responsible for literature review and manuscript review. MN, RD and AS were responsible for literature review.

Corresponding author

Correspondence to Jillian M. Connolly.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics Approval and Consent to Participate

The protocol for this study was approved by the University Hospitals institutional review board. The need for informed consent was waived due to the retrospective nature of the study. This study was performed in accordance with the Declaration of Helsinki.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Connolly, J.M., McClary, J.D., Desai, R. et al. Efficacy of recombinant erythropoietin for the late treatment of anemia of prematurity in a level IV neonatal intensive care unit: a retrospective single-center cohort study. J Perinatol 44, 892–896 (2024). https://doi.org/10.1038/s41372-024-02001-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41372-024-02001-6

Search

Quick links